Skip to main content
SpringerLink
Log in

Erste randomisierte Phase-3-Studie zur adjuvanten Therapie mit einem Tyrosinkinaseinhibitor bei Hochrisiko-Nierenzellkarzinom

First randomized phase 3 study on adjuvant therapy with a tyrosine kinase inhibitor in high-risk renal cell carcinoma

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. Journal of clinical oncology: official journal of the American Society of. Clin Oncol 19(2):425–431

    CAS  Google Scholar 

  2. Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB et al (2015) Effects of adjuvant Sorafenib and Sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: results from ASSURE, ECOG 2805. Clin Cancer Res 21(18):4048–4054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173(1):48–51

    Article  PubMed  Google Scholar 

  4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  CAS  PubMed  Google Scholar 

  5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Heidelberg, NCT-Heidelberg INF 460, 69120, Heidelberg, Deutschland

    Carsten Grüllich

Authors
  1. Carsten Grüllich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten Grüllich.

Ethics declarations

Interessenkonflikt

PD Dr. C. Grüllich gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grüllich, C. Erste randomisierte Phase-3-Studie zur adjuvanten Therapie mit einem Tyrosinkinaseinhibitor bei Hochrisiko-Nierenzellkarzinom. Onkologe 22, 886–888 (2016). https://doi.org/10.1007/s00761-016-0096-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-016-0096-3

Search

Navigation